Immuron (ASX:IMC) entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.
Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.
The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.
Company shares were down nearly 3% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.